Conclusion We have demonstrated that despite concerns regarding the suit-ability of CPV-2 (or variant) vaccine isolates to provide protectionagainst the other CPV-2 derivatives that vaccination with a new multivalent vaccine, containing CPV-2b, stimulates high serologicalresponses to CPV-2a and CPV-2c and lower responses to CPV-2.